Abstract
Diabetes mellitus is a major contributor to kidney failure, with diabetic nephropathy being a common microvascular complication. The increasing prevalence of diabetes and its complications suggests a rise in associated morbidity and mortality. Recent studies highlight increased mortality related to diabetic kidney disease, with disparities across demographic and geographic groups. Novel pharmacological treatments, including sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 agonists, offer promise in slowing disease progression and reducing renal mortality. However, the growing epidemics of obesity and diabetes necessitate prioritizing public health policies focused on primary and secondary prevention, along with comprehensive multidisciplinary care.